Oncology & Cancer

Results of major myeloma treatment trial published

The addition of bortezomib to a standard two-drug regimen for multiple myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives, according to clinical trial ...

Oncology & Cancer

Low dose of targeted drug might improve cancer-killing virus therapy

Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive ...

Oncology & Cancer

Cancer drug boosts levels of vascular-protective gene, KLF2

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

Oncology & Cancer

Novel drug regimen can improve stem cell transplantation outcomes

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to ...

page 1 from 4

Bortezomib

Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

This text uses material from Wikipedia, licensed under CC BY-SA